drugset / Trial / NCT00004933
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Phase 3
Terminated
5 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if homoharringtonine is more effective than hydroxyurea for chronic myelogenous leukemia that has not responded to interferon alfa. PURPOSE: Randomized phase III trial to compare the effectiveness of homoharringtonine with that of hydroxyurea in treating patients who have chronic myelogenous leukemia that has not responded to interferon alfa.
Timeline
- Start
- 2000-01
- Primary completion
- 2001-05
- Completion
- 2001-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Homoharringtonine | Small molecule | 2.5 mg/m2 | Intravenous |
| Comparator | Hydroxyurea | Other / unclassified | 0.5 g | Oral |
| Comparator | Hydroxyurea | Other / unclassified | 5 g | Oral |